By IANS
Bangalore : Biocon Ltd, the country’s leading biotechnology firm, has received approval from Drug Controller General of India (DCGI) to market Abraxane, a new drug to treat breast cancer.
The drug, manufactured by US-based Abraxis BioScience Inc, will be sold under licence, according to a company statement released here Thursday.
“Abraxane eliminates the need for pre-medication with steroids or antihistamines. It will also facilitate affordable access to supportive care therapy to cancer patients in India,” the statement pointed out.
“Abraxane is also being clinically studied worldwide in a variety of other oncology settings. Currently, the US firm intends to focus its trials in first-line meta-static breast cancer, first-line non-small cell lung cancer and melanoma by developing superiority trials using weekly dosing schedules,” the statement added.